CSF microRNA Profiling in Alzheimer’s Disease: a Screening and Validation Study

Adrià Dangla-Valls, José Luis Molinuevo, Jordi Altirriba, Raquel Sánchez-Valle, Daniel Alcolea, Juan Fortea, Lorena Rami, Mircea Balasa, Cristina Muñoz-García, Mario Ezquerra, Rubén Fernández-Santiago, Alberto Lleó, Albert Lladó, Anna Antonell

    Research output: Contribution to journalArticleResearchpeer-review

    32 Citations (Scopus)


    © 2016, Springer Science+Business Media New York. MicroRNAs (miRNAs) are short non-coding RNA molecules that regulate gene expression through post-transcriptional repression of target genes. They have been shown to be implicated in the pathophysiology of Alzheimer’s disease (AD) and proposed as disease biomarkers. In the present work, we have studied the expression levels of 754 miRNAs in cerebrospinal fluid (CSF) from AD patients and control subjects. We have explored a first screening cohort (N = 20) and selected 12 miRNAs to be further tested in a second independent validation cohort (N = 69). We have found a significant upregulation of miR-222 and miR-125b in AD CSF. Of these, the association of miR-222 with AD is novel and reported here for the first time whereas upregulation of miR-125b has been previously reported in AD brain. Yet we do not find association with other miRNAs which were previously linked to AD. Our results shed light on potential underlying pathophysiological processes of AD and also point out the need for consensus procedures in CSF miRNA detection and data analysis.
    Original languageEnglish
    Pages (from-to)6647-6654
    JournalMolecular Neurobiology
    Issue number9
    Publication statusPublished - 1 Nov 2017


    • Alzheimer’s disease
    • Biomarkers
    • Cerebrospinal fluid
    • miR-125b
    • miR-222
    • microRNAs


    Dive into the research topics of 'CSF microRNA Profiling in Alzheimer’s Disease: a Screening and Validation Study'. Together they form a unique fingerprint.

    Cite this